Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.
OBJECTIVE
Cystic lesions of the pancreas are increasingly being recognized due to the widespread use of high resolution abdominal imaging. Since certain cyst types are precursors to invasive cancer, this situation presents an opportunity to intervene prior to malignant progression. Effective implementation of that strategy has been hampered by difficulties in clearly distinguishing cystic lesions with no malignant potential from those with malignant potential. Here we explored whether glycosylation variants on specific proteins in cyst fluid samples could serve as biomarkers to aid in this diagnosis.


METHODS
We used a novel antibody-lectin sandwich microarray method to measure the protein expression and glycosylation of mucin (MUC)1, MUC5AC, MUC16, carcinoembryonic antigen, and other proteins implicated in pancreatic neoplasia in cyst fluid samples. Fifty-three cyst fluid samples were obtained from patients with mucinous cystic neoplasms (n=17), intraductal papillary mucinous neoplasms (n=15), serous cystadenomas (n=12), or pseudocysts (n=9), with confirmation of histologic diagnosis at surgical resection.


RESULTS
The detection of a glycan variant on MUC5AC using the lectin wheat-germ agglutinin discriminated mucin-producing cystic tumors (mucinous cystic neoplasms+intraductal papillary mucinous neoplasms) from benign cystic lesions (serous cystadenomas+pseudocysts) with a 78% sensitivity at 80% specificity, and when used in combination with cyst fluid CA 19-9 gave a sensitivity of 87% at 86% specificity. These biomarkers performed better than cyst fluid carcinoembryonic antigen (37%/80% sensitivity/specificity).


CONCLUSIONS
These results demonstrate the value of glycan variants for biomarker discovery and suggest that these biomarkers could greatly enhance the accuracy of differentiating pancreatic cystic tumors. Validation studies will be required to determine the clinical value of these markers.
Haab
Brian B
BB
Van Andel Research Institute, Grand Rapids, MI, USA.
Porter
Andrew
A
Yue
Tingting
T
Li
Lin
L
Scheiman
James
J
Anderson
Michelle A
MA
Barnes
Dawn
D
Schmidt
C Max
CM
Feng
Ziding
Z
Simeone
Diane M
DM
D014408:Biomarkers, Tumor / Q000032:analysis*; D044963:Biopsy, Fine-Needle; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D020420:Cyst Fluid / Q000737:chemistry*; D003536:Cystadenocarcinoma / Q000737:chemistry; D018291:Cystadenoma, Mucinous / Q000737:chemistry; D018293:Cystadenoma, Serous / Q000737:chemistry; D006031:Glycosylation; D006801:Humans; D007091:Image Processing, Computer-Assisted; D016015:Logistic Models; D055271:Mucin 5AC / Q000032:analysis; D009077:Mucins / Q000032:analysis*; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000175:diagnosis*; D010192:Pancreatic Pseudocyst / Q000737:chemistry / Q000175:diagnosis; D040081:Protein Array Analysis; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; C524678:MUC5AC protein, human; D055271:Mucin 5AC; D009077:Mucins
Int J Cancer. 2006 Jun 1;118(11):2803-8
16385567
Proteomics. 2008 Aug;8(16):3257-62
18646007
Int J Cancer. 1991 Jan 21;47(2):180-7
1988363
Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665
16682259
Am J Surg Pathol. 2004 Aug;28(8):977-87
15252303
Pancreas. 2007 May;34(4):466-9
17446847
Nat Rev Cancer. 2004 Jan;4(1):45-60
14681689
Gastrointest Endosc. 2009 May;69(6):1103-5
19410042
J Proteome Res. 2007 May;6(5):1864-74
17428079
J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79
11307091
J Biol Chem. 1997 Sep 26;272(39):24198-202
9305871
Int J Cancer. 1997 Jun 20;74(3):286-90
9221806
J Gastrointest Surg. 2004 Jul-Aug;8(5):569-74
15239993
Mod Pathol. 2007 Feb;20 Suppl 1:S71-93
17486054
J Mol Med (Berl). 1997 Aug;75(8):594-602
9297627
EMBO Rep. 2006 Jun;7(6):599-604
16741504
J Clin Oncol. 2006 Jun 20;24(18):2897-902
16782929
Br J Cancer. 2004 Nov 1;91(9):1633-8
15494719
Pancreatology. 2007;7(1):9-19
17449961
Nat Methods. 2007 May;4(5):437-44
17417647
Br J Cancer. 1988 Nov;58(5):589-93
3265332
Biochim Biophys Acta. 1999 Dec 6;1473(1):21-34
10580127
Br J Cancer. 1991 Aug;64(2):386-90
1892771
Pathobiology. 2001;69(3):127-35
11872958
Gastroenterology. 2004 May;126(5):1330-6
15131794
Biochem Biophys Res Commun. 1994 Jan 14;198(1):318-27
8292036
Cancer Res. 2005 Dec 1;65(23):11193-202
16322270
Gastrointest Endosc. 2005 Sep;62(3):383-9
16111956
Glycoconj J. 1997 Aug;14(5):585-91
9298691
Pathol Res Pract. 2000;196(4):259-63
10782470
J Hepatol. 2000 Jun;32(6):946-54
10898315
J Gastroenterol Hepatol. 1999 May;14(5):436-45
10355508
Am J Epidemiol. 1998 Feb 15;147(4):407-13
9508109
Ann Surg. 2004 May;239(5):651-7; discussion 657-9
15082969
Cancer Res. 1997 Dec 1;57(23):5201-6
9393734
Clin Gastroenterol Hepatol. 2005 Oct;3(10):967-73
16234041
Clin Cancer Res. 2000 Aug;6(8):2969-72
10955772
J Proteome Res. 2009 Feb;8(2):483-92
19072160
Int J Cancer. 1996 Aug 22;69(4):290-4
8797870
Int J Cancer. 1993 Jul 30;54(6):972-7
7687590
Glycoconj J. 2007 Nov;24(8):411-20
17457671
Immunol Cell Biol. 2005 Aug;83(4):429-39
16033539
Am J Surg Pathol. 1999 Nov;23(11):1320-7
10555000
Mol Oncol. 2007 Sep;1(2):216-25
19305640
Ann Surg. 2006 May;243(5):673-80; discussion 680-3
16633003